Product logins

Find logins to all Clarivate products below.


Scleroderma (Systemic Sclerosis) | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2021

Systemic sclerosis (SSc) is a rare, progressive, debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin thickening, and, often, painful digital ulcers. Mortality risks of pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), and renal crisis are high in SSc patients. The only disease-modifying therapies (DMTs) approved for SSc are Boehringer Ingelheim’s Ofev (nintedanib) and Roche / Genentech’s Actemra / RoActemra (tocilizumab), both of which target the SSc-ILD subpopulation and have demonstrated the ability to slow the progressive loss of lung function. The mid-phase SSc pipeline is large and diverse. Although there is tremendous need for additional effective DMTs, drug development in SSc has been historically challenging due to the heterogeneity of SSc patients and the commensurate challenges with trial design.

QUESTIONS ANSWERED

· How large is the diagnosed SSc population in the United States and EU5, and how will it change over time?

· What is the current treatment landscape in SSc, and how will it change in the next 10 years?

· What do key opinion leaders view as the greatest unmet medical needs in the management of SSc?

· What is the commercial potential of key emerging therapies? How will they fit into the SSc treatment landscape?

PRODUCT DESCRIPTION

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…